• Explore /
  • Poster
  • / Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.

Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.

Abstract Poster

Authors

null

Kevin W. Song

Vancouver General Hospital, Vancouver, BC, Canada

Kevin W. Song , Meletios A. Dimopoulos , Katja C. Weisel , Philippe Moreau , Martha Lacy , Michel Delforge , Lionel Karlin , Hartmut Goldschmidt , Anne Banos , Albert Oriol Rocafiguera , Stacie Hudgens , Zhinuan Yu , Lars Sternas , Christian Jacques , Mohamed H. Zaki , Jesùs F. San-Miguel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01311687

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8583)

DOI

10.1200/jco.2013.31.15_suppl.8583

Abstract #

8583

Poster Bd #

53D

Abstract Disclosures

Similar Posters

First Author: Katja Weisel

First Author: Philippe Moreau

First Author: Dan T. Vogl

First Author: Gareth J Morgan